The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart ...

Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

Rhythm Heaven is back! Get a new look at the new entry Rhythm Heaven: Groove in this gameplay trailer. Rhythm Heaven: Groove ...

Rhythm Heaven is back! Get a new look at the new entry Rhythm Heaven: Groove in this gameplay trailer. Rhythm Heaven: Groove ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and ...

The integration of AI and cloud technologies is transforming pharmaceutical manufacturing regulations, focusing on safety, efficiency, and global harmonization.

Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued on Monday, March 24th. HC Wainwright analyst R.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

10 analysts have shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...